198 related articles for article (PubMed ID: 33146973)
1. Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review.
Fantin JPP; Furst MCB; Tobias-Machado M; Muller RL; Machado RD; Santos AC; Magnabosco WJ; Alcantara-Quispe C; Faria EF
Int Braz J Urol; 2021; 47(3):484-494. PubMed ID: 33146973
[TBL] [Abstract][Full Text] [Related]
2. Surgical management of high-risk, localized prostate cancer.
Wilkins LJ; Tosoian JJ; Sundi D; Ross AE; Grimberg D; Klein EA; Chapin BF; Nyame YA
Nat Rev Urol; 2020 Dec; 17(12):679-690. PubMed ID: 33173205
[TBL] [Abstract][Full Text] [Related]
3. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; van der Kwast TH; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; van der Poel HG; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Cornford P
Eur Urol; 2021 Feb; 79(2):243-262. PubMed ID: 33172724
[TBL] [Abstract][Full Text] [Related]
4. Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments.
Fossati N; Giannarini G; Joniau S; Sedelaar M; Sooriakumaran P; Spahn M; Rouprêt M;
Eur Urol Oncol; 2022 Oct; 5(5):587-600. PubMed ID: 33249083
[TBL] [Abstract][Full Text] [Related]
5. Detection Rate of
Brumberg J; Beckl M; Dierks A; Schirbel A; Krebs M; Buck A; Kübler H; Lapa C; Seitz AK
Biomedicines; 2020 Nov; 8(11):. PubMed ID: 33217931
[TBL] [Abstract][Full Text] [Related]
6. Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality.
Shih HJ; Fang SC; An L; Shao YJ
Prostate; 2021 Feb; 81(2):118-126. PubMed ID: 33152137
[TBL] [Abstract][Full Text] [Related]
7. Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box.
Fleming CW; Broughman JR; Tendulkar RD
Curr Treat Options Oncol; 2020 Nov; 22(1):2. PubMed ID: 33216272
[TBL] [Abstract][Full Text] [Related]
8. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
[TBL] [Abstract][Full Text] [Related]
9. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
Labriola MK; Atiq S; Hirshman N; Bitting RL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
[TBL] [Abstract][Full Text] [Related]
10. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M; Terada N; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Mizowaki T; Kamoto T; Kojima T; Kitamura H; Sugimoto M; Nishiyama H; Eto M;
Cancer Sci; 2021 Apr; 112(4):1524-1533. PubMed ID: 33159829
[TBL] [Abstract][Full Text] [Related]
11. Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
Meijer D; Donswijk ML; Bodar YJL; van Leeuwen PJ; Poel HGV; Vogel WV; Nieuwenhuijzen JA; Hendrikse NH; Oprea-Lager DE; Vis AN
J Nucl Med; 2021 Jul; 62(7):961-967. PubMed ID: 33158904
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Prostate Cancer Treatment on Quality of Life: A Narrative Review with a Focus on Randomized Data.
Taylor JM; Chen VE; Miller RC; Greenberger BA
Res Rep Urol; 2020; 12():533-546. PubMed ID: 33150144
[TBL] [Abstract][Full Text] [Related]
13. Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial.
Xiao YT; Zhao X; Chang Y; Lu X; Wang Y; Zhang H; Ren S
BMJ Open; 2020 Nov; 10(11):e038678. PubMed ID: 33148738
[TBL] [Abstract][Full Text] [Related]
14. Secondary malignancy risk for patients with localized prostate cancer after intensity-modulated radiotherapy with and without flattening filter.
Treutwein M; Loeschel R; Hipp M; Koelbl O; Dobler B
J Appl Clin Med Phys; 2020 Dec; 21(12):197-205. PubMed ID: 33147377
[TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer.
Stone BV; Laviana AA; Luckenbaugh AN; Huang LC; Zhao Z; Koyama T; Conwill R; Hoffman K; Joyce DD; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
J Urol; 2021 Mar; 205(3):761-768. PubMed ID: 33252300
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
Uemura H; Matsushima H; Kobayashi K; Mizusawa H; Nishimatsu H; Fizazi K; Smith M; Shore N; Tammela T; Tabata KI; Matsubara N; Iinuma M; Uemura H; Oya M; Momma T; Kawakita M; Fukasawa S; Kobayashi T; Kuss I; Le Berre MA; Snapir A; Sarapohja T; Suzuki K
Int J Clin Oncol; 2021 Mar; 26(3):578-590. PubMed ID: 33226524
[TBL] [Abstract][Full Text] [Related]
18. What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes.
Lopez P; Taaffe DR; Newton RU; Buffart LM; Galvão DA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):465-481. PubMed ID: 33219369
[TBL] [Abstract][Full Text] [Related]
19. Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
de Wit R; Tombal B; Freedland S
Eur Urol; 2021 Feb; 79(2):170-172. PubMed ID: 33218827
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.
Procopio G; Chiuri VE; Giordano M; Mantini G; Maisano R; Bordonaro R; Calvani N; Facchini G; De Placido S; Airoldi M; Sbrana A; Gasparro D; Ludovico GM; Guglielmini P; Naglieri E; Fagnani D; Aglietta M; Schips L; Beccaglia P; Sciarra A; Livi L; Santini D
Ther Adv Med Oncol; 2020; 12():1758835920968725. PubMed ID: 33193831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
